Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
暂无分享,去创建一个
A Garaventa | S Parodi | R Haupt | S. Parodi | S. Navarro | K. Beiske | M. Peuchmaur | C. Gambini | R. Haupt | C. Cullinane | G. Erminio | A. Garaventa | P. Brock | F. Casale | K Beiske | D. Valteau‐Couanet | H Rubie | C Munzer | D Valteau-Couanet | V. Castel | H. Rubié | J. Kohler | K. Holmes | C. Munzer | C. Márquez | C. Cullinane | V Castel | S Navarro | J A Kohler | K Holmes | C Gambini | F Casale | G Erminio | C Marquez | M Peuchmaur | C Cullinane | P Brock | Stefano Parodi | Riccardo Haupt | Giovanni Erminio
[1] G. Tonini,et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Giovanni Cecchetto,et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Halperin,et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. , 1997, European journal of cancer.
[4] D. Stram,et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Gerald,et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[7] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[8] O. Delattre,et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] K. Matthay,et al. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. , 2004, Journal of pediatric surgery.
[10] Ruth Ladenstein,et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] V. Castel,et al. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. , 1995, Medical and pediatric oncology.
[13] F. Berthold,et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. , 2011, European journal of cancer.
[14] B. Hero,et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. , 2011, Radiology.
[15] J. Shuster,et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Leverger,et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). , 1998, British Journal of Cancer.
[17] P. Bruzzi,et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group , 2008, British Journal of Cancer.
[18] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[19] A. Look,et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. , 2010, The New England journal of medicine.
[20] F. Berthold,et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Korf,et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[23] A. Donfrancesco,et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Cheung,et al. Management and outcome of stage 3 neuroblastoma. , 2009, European journal of cancer.
[25] C. Bergeron,et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy , 2003, British Journal of Cancer.
[26] Giovanni Cecchetto,et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Samuel Navarro,et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Maris,et al. Outcome of high‐risk stage 3 neuroblastoma with myeloablative therapy and 13‐cis‐retinoic acid: A report from the Children's Oncology Group , 2009, Pediatric blood & cancer.
[29] F. Speleman,et al. Quality assessment of genetic markers used for therapy stratification. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.